Corporate Banner
Satellite Banner
Metabolomics & Lipidomics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Agilent Thought Leader Award Supports Dr. Junying Yuan, Chinese Academy of Sciences

Published: Wednesday, December 11, 2013
Last Updated: Wednesday, December 11, 2013
Bookmark and Share
Integrated biological research is accelerating drug development for neurodegenerative diseases.

Agilent announce that Dr. Junying Yuan, a pioneer and leading researcher in the field of cell death at the Chinese Academy of Sciences, has received an Agilent Thought Leader award in recognition of her scientific contributions to cellular biology and the understanding of neurodegenerative diseases.

Dr. Yuan heads the Chinese Academy of Science's newly established Interdisciplinary Research Center on Biology and Chemistry. She plans to use Agilent's integrated biology technologies to expand her metabolomics-based approach for studying neurodegenerative diseases and gain deeper insights into neurodegenerative processes.

"Integrating our metabolomics data with transcriptomic and proteomic data will allow us to better study disease pathogenesis by more fully understanding underlying disease biology," said Dr. Yuan. "Our aim is to identify five to 10 protein targets or biomarkers for neurodegenerative diseases within the next three years."

Dr. Yuan and her team, headed by mass spectrometry specialist Dr. Zhengjiang Zhu, seek important insights into the complex interactions of metabolite-protein, protein-protein and genetic networks involved in the etiology of neurodegenerative disease. They will use Agilent's metabolomics workflows and integrated biology software solutions,6400 Series Triple Quadrupole LC/MS system, and GeneSpring software in their work.

Dr. Yuan's research has uncovered many significant distinctions in the multiple cell death mechanisms, including programmed cell death (apoptosis) and necroptosis elicited by external factors such as infection, toxins or trauma (necrosis). Her recent work focuses on the identification of necrostatins, a family of small molecule inhibitors of necroptosis, which is a regulated necrotic cell death mechanism.

Dr. Yuan also holds a professorship in Cell Biology at Harvard University and has published more than 160 peer-reviewed journal articles. She is a member of the American Academy of Arts and Sciences and a fellow of the American Association for Advancement of Science. She serves as senior editor of the Journal of Cell Biology and the Journal of Cell Death & Disease and holds 12 U.S. patents. Dr. Yuan's research has received the National Institutes of Health Director's Pioneer Award and the Innovator's Award for Breast Cancer Research.

"Researchers using an integrated approach to the study of biology are gaining significant insights into the complex interactions between genes, proteins and metabolites, which are accelerating the discovery of new therapies to treat serious neurodegenerative disorders such as Alzheimer's and Parkinson's disease," said Patrick Kaltenbach, Agilent's vice president and general manager of the LC/MS business. "We are honored to support Dr. Yuan and the Chinese Academy of Sciences in their pioneering research in this area."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Agilent Completes Acquisition of Seahorse Bioscience
Agilent has completed the acquisition of Seahorse Bioscience, a leader in providing instruments and assay kits for measuring cell metabolism and bioenergetics.
Tuesday, November 03, 2015
Agilent Announces Opening of Life Science Research Center
Facility designed to advance multi-omics research.
Thursday, September 24, 2015
Agilent to Acquire Seahorse Bioscience
Acquisition complements Agilent’s market-leading separations and mass spectrometry solutions, expands pharma offerings.
Thursday, September 10, 2015
Agilent to Focus on "Powerful Partnerships, Inspiring Results" at ASMS 2015
Company to introduce solutions enabling new standards in mass spectrometry, lab productivity.
Friday, May 29, 2015
Agilent, Baylor Open Mass Spec Center of Excellence
The new facility aims to boost metabolomics research at Baylor College of Medicine.
Friday, December 05, 2014
Agilent Thought Leader Award Supports Metabolic Research
Princeton team developing LC/MS methods, bioinformatics tools for discovery of metabolic regulatory mechanisms.
Tuesday, April 22, 2014
Agilent to Host Young Scientist Forums in Asia Pacific
Events provide platform for rising talents in Australia, Singapore to exchange ideas with leading scientific scholars.
Wednesday, March 26, 2014
Agilent, CambTEK Announce LC Sample Prep Agreement
Companies announce agreement to co-market CambTEK's RES automated sample preparation technology with an assortment of Agilent's instruments and software.
Wednesday, February 26, 2014
Agilent Awards Grant for Translational Research in Cardiometabolic Disease
Dr. Christopher Newgard's team at Duke University use Agilent platforms to better understand disease mechanisms.
Thursday, January 16, 2014
Agilent Reports Fourth-Quarter Results
Agilent Technologies reported orders up 4 percent over one year ago to $1.83 billion with revenues of $1.72 billion, down 3 percent compared with one year ago.
Monday, November 18, 2013
Agilent Recognized as 2013 Laboratory Analytical Instrumentation Company of the Year in China
The company ranked highest in industry for leadership, growth, innovation and customer service by Frost & Sullivan.
Tuesday, August 20, 2013
Agilent and SRI International Sign Licensing Agreement
Agilents’ new pathway Architect software to include SRI International’s BioCyc Pathway database collection.
Wednesday, April 17, 2013
Agilent and Spain’s Centre for Omic Sciences to Collaborate
Both Companies collaborate on integrated systems biology research, establish centre of excellence.
Tuesday, March 05, 2013
Agilent Technologies Thought Leader Award Supports Translational Research Program
The award will support Dr DePinho's research into metabolic reprogramming in the earliest stages of cancer.
Monday, March 04, 2013
Dr. Robert Gerszten Receives Agilent Thought Leader Award
Award supports Dr. Gerszten's work in metabolomic research at Massachusetts General Hospital.
Thursday, December 20, 2012
Scientific News
Gut Microbes Signal to the Brain When They're Full
Don't have room for dessert? The bacteria in your gut may be telling you something.
Turning up the Tap on Microbes Leads to Better Protein Patenting
Mining millions of proteins could become faster and easier with a new technique that may also transform the enzyme-catalyst industry, according to University of California, Davis, researchers.
Drug May Prevent Life-Threatening Muscle Loss in Advanced Cancers
New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health.
Cancer-Fighting Tomato Component Traced
The metabolic pathway associated with lycopene, the bioactive red pigment found in tomatoes, has been traced by researchers at the University of Illinois.
Circadian Clock Controls Insulin and Blood Sugar in Pancreas
Map of thousands of genes suggests new therapeutic targets for diabetes.
Cellular Stress Process Identified in Cardiovascular Disease
Combining the investigative tools of genetics, transcriptomics, epigenetics and metabolomics, a Duke Medicine research team has identified a new molecular pathway involved in heart attacks and death from heart disease.
Predicting Adverse Drug Reactions with Higher Confidence
A new integrated computational method helps predicting adverse drug reaction—which are often lethal—more reliably than with traditional computing methods.
A New Way to Starve Lung Cancer?
Metabolic alterations in lung cancer may open new avenues for treating the disease.
Evidence of How Incurable Cancer Develops
Researchers in the West Midlands have made a breakthrough in explaining how an incurable type of blood cancer develops from an often symptomless prior blood disorder.
Building a Better Liposome
Computational models suggest new design for nanoparticles used in targeted drug delivery.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos